Urine specimen detection of concurrent nonprescribed medicinal and illicit drug use in patients prescribed buprenorphine

Journal of Analytical Toxicology

Volumn 37, Issue 9, 2013, Pages 636-641

  Guo, Alexander Y ^a   Ma, Joseph D ^a,b   Best, Brookie M ^a,c   Atayee, Rabia S ^a,b  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b Doris A Howell Palliative Care Service   (United States)

^c RADY CHILDREN'S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; BUPRENORPHINE; CANNABIS; COCAINE; CODEINE; DIAMORPHINE; FENTANYL; HERBACEOUS AGENT; HYDROCODONE; ILLICIT DRUG; METHADONE; METHAMPHETAMINE; MORPHINE; NORBUPRENORPHINE; OXYCODONE;

ARTICLE; DRUG DETERMINATION; DRUG URINE LEVEL; DRUG USE; GAS CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; PRESCRIPTION; RETROSPECTIVE STUDY; URINALYSIS;

BIOTRANSFORMATION; BUPRENORPHINE; CHROMATOGRAPHY, GAS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHRONIC PAIN; DRUG INTERACTIONS; HUMANS; NARCOTICS; OPIOID-RELATED DISORDERS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; STREET DRUGS; SUBSTANCE ABUSE DETECTION; SUBSTANCE-RELATED DISORDERS; TANDEM MASS SPECTROMETRY; TREATMENT OUTCOME;

EID: 84885736416     PISSN: 01464760     EISSN: 19452403     Source Type: Journal    
DOI: 10.1093/jat/bkt082     Document Type: Article

References (29)

1. Flippen-Anderson, J.L., George, C., Bertha, C.M., Rice, K.C. (1994) X-ray crystal structures of potent opioid receptor ligands: etonitazene, cis-(+)-methylfentanyl, etorphine, diprenorphine, and buprenorphine. Heterocycles, 39, 751-766.
2. Johnson, R.E., Strain, E.C., Amass, L. (2003) Buprenorphine: how to use it right. Drug Alcohol Dependendence, 70, S59-S77.
3. Chang, Y., Moody, D.E., McCance-Katz, E.F. (2006) Novel metabolites of buprenorphine detected in human liver microsomes and human urine. Drug Metabolism and Disposition, 34, 440-448.
4. Ohtani, M. (2007) Basic pharmacology of buprenorphine. European Journal of Pain Supplement, 1, 69-73.
5. Walsh, S.L., Preston, K.L., Bigelow, G.E., Stitzer, M.L. (1995) Acute administration of buprenorphine in humans: partial agonist and blockade effects. Journal of Pharmacology and Experimental Therapeutics, 274, 361-372.
6. Fudala, P.J., Bridge, T.P., Herbert, S., Williford, W.O., Chiang, C.N., Jones, K. et al. (2003) Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. New England Journal of Medicine, 349, 949-958.
7. Myers, D.P., Augustyniak, M., Molea, J. (2005) Buprenorphine for pain management physicians: a dilemma or a therapeutic alternative? Techniques in Regional Anesthesia and Pain Management, 9, 216-220.
8. Middleton, L.S., Nuzzo, P.A., Lofwall, M.R., Moody, D.E., Walsh, S.L. (2011) The pharmacodynamic and pharmacokinetic profile of intranasal crushed buprenorphine and buprenorphine/naloxone tablets in opioid abusers. Addiction, 106, 1460-1473.
9. Trescot, A.M., Boswell, M.V., Atluri, S.L., Hansen, H.C., Deer, T.R., Abdi, S. et al. (2006) Opioid guidelines in the management of chronic noncancer pain. Pain Physician, 9, 1-39.
10. Cone, E.J., Caplan, Y.H., Black, D.L., Robert, T., Moser, F. (2008) Urine drug testing of chronic pain patients: licit and illicit drug patterns. Journal of Analytical Toxicology, 32, 530-543.
11. Mikel, C., Almazan, P., West, R., Crews, B., Latyshev, S., Pesce, A. et al. (2009) LC-MS/MS extends the range of drug analysis in pain patients. Therapeutic Drug Monitoring, 31, 746-748.
12. Mohsin, S., Zumwalt, M. (2007) Quantitative analysis of opiates in urine using RRHT LC/MS/MS. Santa Clara, CA: Agilent Technologies.
13. Pesce, A., Rosenthal, M., West, R., West, C., Crews, B., Mikel, C. et al. (2010) An evaluation of the diagnostic accuracy of liquid chromatography-tandem mass spectrometry versus immunoassay drug testing in pain patients. Pain Physician, 13, 273-281.
14. West, R., Pesce, A., West, C., Crews, B., Mikel, C., Almazan, P. et al. (2010) Comparison of clonazepam compliance by measurement of urinary concentration by immunoassay and LC-MS/MS in pain management population. Pain Physician, 13, 71-78.
15. Heit, H.A., Gourlay, D.L. (2004) Urine drug testing in pain medicine. Journal of Pain and Symptom Management, 27, 260-267.
16. McCance-Katz, E.F., Ralney, P.M., Moody, D.E. (2009) Effect of cocaine use on buprenorphine pharmacokinetics in humans. American Journal of Addictions, 19, 38-46.
17. Pesce, A., West, C., Rosenthal, M., West, R., Crews, B., Mikel, C. et al. (2010) Marijuana correlates with use of other illicit drugs in a pain patient population. Pain Physician, 13, 283-287.
18. Pesce, A., West, C., Rosenthal, M., Mikel, C., West, R., Crews, B. et al. (2011) Illicit drug use in the pain patient population decreases with continued drug testing. Pain Physician, 14, 189-193.
19. Seldé n, T., Ahlner, J., Druid, H., Kronstrand, R. (2012) Toxicological and pathological findings in a series of buprenorphine related deaths. Possible risk factors for fatal outcome. Forensic Science International, 220, 284-290.
20. Maxwell, J.C., McCance-Katz, E.F. (2009) Indicators of buprenorphine and methadone use and abuse: what do we know? American Journal of Addictions, 19, 73-88.
21. Lintzeris, N., Nielsen, S. (2009) Benzodiazepines, methadone and buprenorphine: interactions and clinical management. American Journal of Addictions, 19, 59-72.
22. Lintzeris, N., Mitchell, T.B., Bond, A., Nestor, L., Strang, J. (2006) Interactions on mixing diazepam with methadone or buprenorphine in maintenance patients. Journal of Clinical Psychopharmacology, 26, 274-283.
23. McCance-Katz, E.F., Sullivan, L.E., Nallani, S. (2009) Drug interactions of clinical importance among the opioids, methadone, and buprenorphine, and other frequently prescribed medications: a review. American Journal of Addictions, 19, 4-16.
24. Gueye, P.N., Borron, S.W., Risede, P., Monier, C., Buneaux, F., Debray, M. et al. (2002) Buprenorphine and midazolam act in combination to depress respiration in rats. Toxicological Sciences, 65, 107-114.
25. Chang, Y., Moody, D.E. (2005) Effect of benzodiazepines on the metabolism of buprenorphine in human liver microsomes. European Journal of Clinical Pharmacology, 60, 875-881.
26. Kintz, P. (2001) Deaths involving buprenorphine: a compendium of French cases. Forensic Science International, 121, 65-69.
27. Lai, S.H., Yao, Y.J., Lo, D.S. (2006) A survey of buprenorphine related deaths in Singapore. Forensic Science International, 162, 80-86.
28. Häkkinen, M., Launiainen, T., Vouri, E., Ojanperä , I. (2012) Benzodiazepines and alcohol are associated with cases of fatal buprenorphine poisoning. European Journal of Clinical Pharmacology, 68, 301-309.
29. O'Connor, J.J., Moloney, E., Travers, R., Campbell, A. (1988) Buprenorphine abuse among opiate addicts. British Journal of Addiction, 83, 1085-1087.